Study S003311

A Phase 1/2 Randomized Placebo-Controlled Double-Blind Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Doses of MET097 in Adult Participants With Obesity and Overweight But Otherwise Healthy

ClinicalTrials.gov record

Registration

Registration: NCT06857617
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1; PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 120
Start: 2024-04-01
Primary completion: 2025-01-03
Lead sponsor: Metsera, a wholly owned subsidiary of Pfizer
Conditions: Obesity and Overweight
Interventions: BIOLOGICAL:(Part C) MET097; BIOLOGICAL:(Part C) Placebo
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

(Part C) Percent change from baseline in body weight at Week 12 (Day 85). [Day 1 (Week 0) to Day 85 (Week 12)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.